Related references
Note: Only part of the references are listed.Cep55/c10orf3, a Tumor Antigen Derived From a Centrosome Residing Protein in Breast Carcinoma
Satoko Inoda et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients
Jun-ichi Kobayashi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Bcl-2-family proteins and hematologic malignancies: history and future prospects
John C. Reed
BLOOD (2008)
The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers
J. Nakano et al.
BRITISH JOURNAL OF CANCER (2008)
A cryptic vascular endothelial growth factor T-cell epitope: Identification and characterization by mass spectrometry and T-cell assays
Andreas O. Weinzierl et al.
CANCER RESEARCH (2008)
Immunogenicity of the hTERT540-548 peptide in cancer
Lynn Wenandy et al.
CLINICAL CANCER RESEARCH (2008)
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer
Tetsuhiro Tsuruma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
Ittai Ben-Porath et al.
NATURE GENETICS (2008)
Cancer stem cells, CD200 and immunoevasion
Brian T. Kawasaki et al.
TRENDS IN IMMUNOLOGY (2008)
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Jane E. Visvader et al.
NATURE REVIEWS CANCER (2008)
The universal character of the tumour-associated antigen survivin
Mads Hald Andersen et al.
CLINICAL CANCER RESEARCH (2007)
The HLA A*0201-restricted hTERT540-548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor
Marco A. Purbhoo et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Expression of livin in renal cell carcinoma and detection of anti-livin autoantibody in patients
Hiroshi Kitamura et al.
UROLOGY (2007)
Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy
M. Schmitz et al.
BRITISH JOURNAL OF CANCER (2007)
Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia
Jaewon Choi et al.
BLOOD (2007)
The final touches make perfect the peptide-MHC class I repertoire
Gianna Elena Hammer et al.
IMMUNITY (2007)
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
Paal F. Brunsvig et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin
Marion Wobser et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1
Hidenobu Ishizaki et al.
CLINICAL CANCER RESEARCH (2006)
In vivo expression of survivin and its splice variant survivin-2B:: Impact on clinical outcome in acute myeloid leukemia
Mandy Wagner et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
Mads Hald Andersen et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2006)
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors
Kazutoshi Takahashi et al.
CELL (2006)
Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses
Olivier Adotevi et al.
CLINICAL CANCER RESEARCH (2006)
Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: Implications for specific immunotherapy
Hiroshi Kitamura et al.
UROLOGY (2006)
Matrix metalloproteinases and tumor metastasis
EI Deryugina et al.
CANCER AND METASTASIS REVIEWS (2006)
Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy
H Caldas et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Survivin study: An update of What is the next wave?
Fengzhi Li et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Detection of autoantibodies to survivin and livin in sera from patients with breast cancer
A Yagihashi et al.
CLINICA CHIMICA ACTA (2005)
Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis
M Fabbro et al.
DEVELOPMENTAL CELL (2005)
Differential expression of survivin-2B and survivin-ΔEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC)
X Ling et al.
LUNG CANCER (2005)
Spontaneous immunity against Bcl-XL in cancer patients
MH Andersen et al.
JOURNAL OF IMMUNOLOGY (2005)
αvβ3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen
E Godefroy et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2
S Wada et al.
CANCER RESEARCH (2005)
Identification of an HLA-A1 restricted CTL epitope from Mcl-1
MH Andersen et al.
LEUKEMIA (2005)
Detection of autoantibodies to livin and survivin in Sera from lung cancer patients
A Yagihashi et al.
LUNG CANCER (2005)
Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy
Y Ichiki et al.
LUNG CANCER (2005)
Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer
Z Su et al.
JOURNAL OF IMMUNOLOGY (2005)
The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients
MH Andersen et al.
LEUKEMIA (2005)
A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins
S Idenoue et al.
CLINICAL CANCER RESEARCH (2005)
Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer
B Ryan et al.
BRITISH JOURNAL OF CANCER (2005)
Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP
MH Andersen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2+ cancer patients
H Shomura et al.
BRITISH JOURNAL OF CANCER (2004)
Hla-B35-restricted immune responses against survivin in cancer patients
S Reker et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Vaccination of cancer patients against telomerase induces functional antitumor CD8+T lymphocytes
RH Vonderheide et al.
CLINICAL CANCER RESEARCH (2004)
Incomplete tolerance to the tumour-associated antigen MDM2
F Ramírez et al.
INTERNATIONAL IMMUNOLOGY (2004)
Identification of novel survivin-derived CTL epitopes
S Reker et al.
CANCER BIOLOGY & THERAPY (2004)
The melanoma inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses
MH Andersen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
The centrosome in normal and transformed cells
Q Wang et al.
DNA AND CELL BIOLOGY (2004)
Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase
MR Parkhurst et al.
CLINICAL CANCER RESEARCH (2004)
Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients
H Shomura et al.
EUROPEAN JOURNAL OF CANCER (2004)
Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family
S Shangary et al.
LEUKEMIA (2003)
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction
JC Schmollinger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Validating survivin as a cancer therapeutic target
DC Altieri
NATURE REVIEWS CANCER (2003)
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth
AG Niethammer et al.
NATURE MEDICINE (2002)
Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocyte's and mediates lysis of tumor cells
J Hernández et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy
A Scardino et al.
JOURNAL OF IMMUNOLOGY (2002)
Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells
H Kao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer
T Stanislawski et al.
NATURE IMMUNOLOGY (2001)
The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis
SA Eceles
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2001)
Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting
M Mesri et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes
J Arai et al.
BLOOD (2001)
Telomerase and cancer
JW Shay et al.
HUMAN MOLECULAR GENETICS (2001)
ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas
D Vucic et al.
CURRENT BIOLOGY (2000)
Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
B Minev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer
AO Güre et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
